Novartis Ag

Ciba-geigy Ag

Walter Scherrer

Robert Portmann

Martin Szelagiewicz

Andreas Burkhard

Urs Christoph Hofmeier

The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 &#x212b;, 5.14 &#x212b;, 4.84 &#x212b;, 4.55 &#x212b;, 4.34 &#x212b;, 4.07 &#x212b;, 3.51 &#x212b;, 3.48 &#x212b;, 3.25 &#x212b;, 3.19 &#x212b;, 3.15 &#x212b;, 3.07 &#x212b;, and 2.81 &#x212b;, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof

The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide

Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

The invention relates to a novel process for producing 2-methoxybenzanthrones, starting with 1-aminoanthraquinones, which process is characterized in that, by application of a special reaction medium, namely a dimethylalkanephosphonate, which at the same time acts as a methylation agent in one of the reaction steps, the reaction is performed from beginning to end according to the principle of the single-vessel reaction, that is to say, without isolation of intermediates. The 2-methoxybenzanthrones obtained by this process are important intermediate products for vat dyes.

Process for producing 2-methoxybenzanthrones

Growing community of inventors

Rheinfelden, Switzerland

Walter Scherrer